Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytokinetics (CYTK) Change in Accured Expenses: 2009-2024

Historic Change in Accured Expenses for Cytokinetics (CYTK) over the last 16 years, with Dec 2024 value amounting to $14.2 million.

  • Cytokinetics' Change in Accured Expenses rose 38.21% to $7.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $17.3 million, marking a year-over-year decrease of 52.22%. This contributed to the annual value of $14.2 million for FY2024, which is 17.08% down from last year.
  • As of FY2024, Cytokinetics' Change in Accured Expenses stood at $14.2 million, which was down 17.08% from $17.1 million recorded in FY2023.
  • Cytokinetics' Change in Accured Expenses' 5-year high stood at $17.1 million during FY2023, with a 5-year trough of $7.1 million in FY2020.
  • Over the past 3 years, Cytokinetics' median Change in Accured Expenses value was $14.2 million (recorded in 2024), while the average stood at $14.0 million.
  • Its Change in Accured Expenses has fluctuated over the past 5 years, first soared by 428.27% in 2020, then declined by 27.99% in 2022.
  • Cytokinetics' Change in Accured Expenses (Yearly) stood at $7.1 million in 2020, then soared by 111.61% to $15.1 million in 2021, then declined by 27.99% to $10.8 million in 2022, then skyrocketed by 57.72% to $17.1 million in 2023, then declined by 17.08% to $14.2 million in 2024.